Acadia Pharmaceuticals 2025 Q1 Earnings Strong Performance with Net Income Up 14.7%
Generado por agente de IAAinvest Earnings Report Digest
jueves, 8 de mayo de 2025, 8:41 am ET2 min de lectura
ACAD--
Acadia Pharmaceuticals reported its fiscal 2025 Q1 earnings on May 07th, 2025. The total revenue increased by 18.7% to $244.32 million. Acadia Pharmaceuticals's EPS rose 10.0% to $0.11 in 2025 Q1 from $0.10 in 2024 Q1, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $18.99 million in 2025 Q1, marking 14.7% growth from $16.55 million in 2024 Q1. Remarkably, in 2025 Q1, the company set a new record high for fiscal Q1 net income, the highest in over 20 years. Acadia reiterated its full-year 2025 guidance, projecting total revenues of $1.03 to $1.095 billion. The company achieved these results by successfully expanding its DAYBUE franchise and maintaining strong product momentum for NUPLAZID. The guidance remains in line with previous forecasts, reflecting confidence in continued growth and development.
Revenue
The total revenue of Acadia PharmaceuticalsACAD-- increased by 18.7% to $244.32 million in 2025 Q1, up from $205.83 million in 2024 Q1. Product sales, net, reached $244.32 million, driven by NUPLAZID net sales of $159.7 million, marking a 23% increase from the previous year, and DAYBUE net sales of $84.6 million, which grew by 11% year-over-year.
Earnings/Net Income
Acadia Pharmaceuticals's EPS rose 10.0% to $0.11 in 2025 Q1 from $0.10 in 2024 Q1, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $18.99 million in 2025 Q1, marking 14.7% growth from $16.55 million in 2024 Q1. The EPS increase indicates solid financial performance and successful strategic execution.
Price Action
The stock price of Acadia Pharmaceuticals has edged up 0.99% during the latest trading day, has edged up 1.44% during the most recent full trading week, and has dropped 3.71% month-to-date.
Post-Earnings Price Action Review
The strategy of buying Acadia Pharmaceuticals (ACAD) shares after a revenue drop quarter-over-quarter and holding for 30 days resulted in a 6.69% return, significantly underperforming the benchmark's 84.08% return. Despite the moderate risk and return potential indicated by a CAGR of 1.31% and a Sharpe ratio of 0.15, the strategy faced a maximum drawdown of -14.61%. Investors seeking higher returns may find this strategy less appealing, particularly when compared to broader market performance. The approach highlights the importance of evaluating market conditions and strategic timing for investments in Acadia Pharmaceuticals, considering the volatility and comparative underperformance relative to market trends.
CEO Commentary
"2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter," said Catherine Owen Adams, Chief Executive Officer. DAYBUE has seen meaningful patient growth, reaching a record 954 unique patients, and NUPLAZID continues to gain momentum from a direct-to-consumer campaign. The company is focused on expanding the DAYBUE franchise globally and recently served its first patient outside the U.S. Additionally, topline results for the COMPASS PWS Phase 3 study of ACP-101 are now expected in early Q4 2025, reflecting an optimistic outlook on pipeline advancements.
Guidance
Acadia is reiterating its full-year 2025 guidance, projecting total revenues of $1.03 to $1.095 billion, with NUPLAZID net sales expected between $650 to $690 million and DAYBUE net sales in the range of $380 to $405 million. R&D expenses are now forecasted at $330 to $350 million, up from prior guidance due to the accelerated timeline for the ACP-101 Phase 3 study. SG&A expenses are anticipated to be between $535 to $565 million.
Additional News
Acadia Pharmaceuticals has actively engaged in strategic initiatives to support growth. In May 2025, the company completed a planned 30% expansion of the DAYBUE field force, enhancing its engagement with healthcare professionals treating Rett syndrome patients. This expansion is part of Acadia's broader strategy to strengthen its commercial presence. Additionally, Acadia is set to participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13, 2025, where it will discuss its innovative approaches and pipeline advancements. These initiatives reflect Acadia
Revenue
The total revenue of Acadia PharmaceuticalsACAD-- increased by 18.7% to $244.32 million in 2025 Q1, up from $205.83 million in 2024 Q1. Product sales, net, reached $244.32 million, driven by NUPLAZID net sales of $159.7 million, marking a 23% increase from the previous year, and DAYBUE net sales of $84.6 million, which grew by 11% year-over-year.
Earnings/Net Income
Acadia Pharmaceuticals's EPS rose 10.0% to $0.11 in 2025 Q1 from $0.10 in 2024 Q1, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $18.99 million in 2025 Q1, marking 14.7% growth from $16.55 million in 2024 Q1. The EPS increase indicates solid financial performance and successful strategic execution.
Price Action
The stock price of Acadia Pharmaceuticals has edged up 0.99% during the latest trading day, has edged up 1.44% during the most recent full trading week, and has dropped 3.71% month-to-date.
Post-Earnings Price Action Review
The strategy of buying Acadia Pharmaceuticals (ACAD) shares after a revenue drop quarter-over-quarter and holding for 30 days resulted in a 6.69% return, significantly underperforming the benchmark's 84.08% return. Despite the moderate risk and return potential indicated by a CAGR of 1.31% and a Sharpe ratio of 0.15, the strategy faced a maximum drawdown of -14.61%. Investors seeking higher returns may find this strategy less appealing, particularly when compared to broader market performance. The approach highlights the importance of evaluating market conditions and strategic timing for investments in Acadia Pharmaceuticals, considering the volatility and comparative underperformance relative to market trends.
CEO Commentary
"2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter," said Catherine Owen Adams, Chief Executive Officer. DAYBUE has seen meaningful patient growth, reaching a record 954 unique patients, and NUPLAZID continues to gain momentum from a direct-to-consumer campaign. The company is focused on expanding the DAYBUE franchise globally and recently served its first patient outside the U.S. Additionally, topline results for the COMPASS PWS Phase 3 study of ACP-101 are now expected in early Q4 2025, reflecting an optimistic outlook on pipeline advancements.
Guidance
Acadia is reiterating its full-year 2025 guidance, projecting total revenues of $1.03 to $1.095 billion, with NUPLAZID net sales expected between $650 to $690 million and DAYBUE net sales in the range of $380 to $405 million. R&D expenses are now forecasted at $330 to $350 million, up from prior guidance due to the accelerated timeline for the ACP-101 Phase 3 study. SG&A expenses are anticipated to be between $535 to $565 million.
Additional News
Acadia Pharmaceuticals has actively engaged in strategic initiatives to support growth. In May 2025, the company completed a planned 30% expansion of the DAYBUE field force, enhancing its engagement with healthcare professionals treating Rett syndrome patients. This expansion is part of Acadia's broader strategy to strengthen its commercial presence. Additionally, Acadia is set to participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13, 2025, where it will discuss its innovative approaches and pipeline advancements. These initiatives reflect Acadia
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios